Fact-checked by Grok 2 weeks ago

Microcalcification

Microcalcifications are tiny deposits of calcium salts, typically less than 1 mm in diameter, that form in soft tissues and are often too small to be felt but detectable on imaging studies. They occur in various organs, including the breast, cardiovascular system, thyroid, and testes, with clinical significance depending on location and context—for instance, serving as markers of atherosclerosis in arteries or potential malignancy in breast tissue.^[1]^[2] In breast screening, microcalcifications are a common mammographic finding, appearing in up to 50% of mammograms, usually non-palpable, and visible as fine white specks.^[3]^[4] They often represent benign processes like fibrocystic changes but can indicate early malignancy, such as ductal carcinoma in situ (DCIS) or invasive ductal carcinoma. Microcalcifications are associated with about 42% of nonpalpable breast cancers, present in roughly 50% of malignant lesions versus 20% of benign ones, though only around 20% of suspicious cases are malignant upon biopsy.^[5] Breast tumors with microcalcifications are linked to higher rates of HER2 overexpression, increased recurrence risk, and reduced survival.^[6]^[7] Detection primarily uses mammography for breast cases, evaluating morphology, distribution, and size via the Breast Imaging Reporting and Data System (BI-RADS), where categories 4 and 5 suggest biopsy. Chemically, in breast tissue, they are classified as type I (calcium oxalate, typically benign) or type II (calcium phosphate like hydroxyapatite, often in malignant or high-risk lesions). Suspicious microcalcifications may require stereotactic biopsy for confirmation, enabling early intervention.^[8]^[5]^[9]

Definition and Characteristics

Physical Properties

Microcalcifications are defined as tiny calcium deposits measuring typically less than 1 mm in diameter, often specified as under 0.5 mm, which are not visible to the naked eye but detectable through imaging modalities such as mammography.^[5]^[10]^[7] These deposits form as localized accumulations in soft tissues, appearing as radiopaque specks due to their high calcium content, which contrasts sharply against surrounding low-density tissues on X-ray images.^[11] Chemically, microcalcifications are classified as type I (calcium oxalate dihydrate, typically benign) or type II (calcium phosphate, such as hydroxyapatite, associated with higher risk). The primary composition in breast tissue is type II hydroxyapatite crystals, with the formula Ca₁₀(PO₄)₆(OH)₂, a form of calcium phosphate that imparts their characteristic density of approximately 3.16 g/cm³.^[5]^[12]^[13] Variations in crystal structure lead to differences in density and morphology, including rod-like, spherical, or needle-shaped forms, which influence their radiographic appearance and stability within tissues.^[14]^[15] These crystalline structures are often amorphous in early stages but crystallize into ordered apatite phases, contributing to their persistence.^[16] In radiology, the physical detection threshold for microcalcifications on X-ray imaging, such as mammography, is around 50-100 micrometers, below which visibility diminishes due to resolution limits and tissue superposition effects.^[17]^[18] Smaller deposits, approaching 0.1 mm, may require magnification or advanced techniques for reliable identification, as their signal is attenuated by scatter and noise.^[19] Under histological examination via microscopy, microcalcifications exhibit a granular or crystalline appearance on standard hematoxylin and eosin staining, often appearing as basophilic deposits.^[5] Under polarized light, type I microcalcifications (calcium oxalate) demonstrate birefringence due to their anisotropic crystal lattice, aiding in type identification and distinguishing from non-crystalline deposits or tissue artifacts, whereas type II do not.^[10]^[11] This optical phenomenon, manifesting as bright interference colors in birefringent types, confirms their mineral composition and is particularly useful for pathological analysis.^[20]

Classification Types

Microcalcifications in breast tissue are classified primarily based on their morphology and distribution patterns, which help differentiate benign from malignant lesions. Benign microcalcifications typically exhibit round or amorphous shapes, appearing as smooth, uniform deposits less than 1 mm in size, often associated with fibrocystic changes or secretory material.^[11] Round types generally carry a low malignancy risk (under 5%), while amorphous types have an intermediate risk (approximately 20%). In contrast, suspicious or malignant forms include linear or cast-like morphologies, such as fine linear branching patterns that mimic ductal casts, indicating a higher likelihood of ductal carcinoma in situ (DCIS).^[8] These shape-based distinctions are crucial for initial risk assessment, while linear and branching forms indicate high suspicion (often >50%).^[10]^[8] Distribution patterns further refine classification by evaluating spatial arrangement. Clustered distributions, defined as five or more calcifications within a 1 cm area extending to 2 cm, raise intermediate concern and often warrant further evaluation.^[11] Segmental patterns, confined to a ductal lobe or segment, are highly suspicious for malignancy due to their association with neoplastic processes, whereas regional (>2 cm, non-segmental) or diffuse distributions across the breast are more likely benign, reflecting widespread physiological changes.^[8] Linear distributions along ducts similarly suggest intraductal pathology and elevate suspicion levels.^[10] The Breast Imaging Reporting and Data System (BI-RADS) lexicon standardizes these classifications for mammographic findings, assigning suspicion levels from category 3 (probably benign, <2% malignancy risk, e.g., clustered round calcifications requiring short-term follow-up) to category 5 (highly suggestive of malignancy, >95% risk, e.g., segmental linear branching).^[11] Categories 4A, 4B, and 4C denote low (2-10%), moderate (10-50%), and high (50-95%) suspicion, respectively, guiding biopsy decisions for morphologies like amorphous or fine pleomorphic types.^[8] Specific examples illustrate these distinctions with imaging correlations. Fine pleomorphic microcalcifications, smaller than 0.5 mm with varied, irregular shapes, appear as scattered, granular opacities on magnification mammography and carry a 25-50% malignancy risk, often linked to high-grade DCIS.^[10] Coarse heterogeneous types, measuring 0.5-1 mm with chunky, irregular forms, show moderate suspicion (around 13% risk) and may correlate with benign fibrosis or low-grade lesions on ultrasound or MRI, though biopsy is typically recommended if clustered.^[11] These morphological subtypes, when viewed in cluster or segmental distributions, enhance diagnostic accuracy in predicting underlying pathology.^[8]

Pathophysiology and Causes

Formation Mechanisms

Microcalcifications form through two primary mechanisms: dystrophic and metastatic calcification, each involving distinct biological pathways that lead to the deposition of calcium salts, primarily hydroxyapatite, in tissues. Dystrophic calcification arises in areas of local tissue damage or necrosis, where cell death releases intracellular contents, creating an environment conducive to passive calcium precipitation despite normal serum calcium levels. This process typically begins with the accumulation of calcium phosphate in damaged cells or debris, progressing to organized crystal formation without requiring systemic metabolic derangements.^[21]^[22] In contrast, metastatic calcification occurs in otherwise normal tissues due to systemic hypercalcemia, where an elevated serum calcium-phosphate product exceeds solubility limits, promoting ectopic deposition. This mechanism is driven by conditions such as hyperparathyroidism or chronic kidney disease, leading to calcium salts precipitating in alkaline microenvironments, such as those in the lungs or kidneys, independent of local injury. The process favors sites with high metabolic activity or pH gradients, resulting in fine, diffuse microcalcifications.^[23]^[24] At the cellular level, microcalcification nucleation involves key structures and cell types that facilitate crystal initiation and growth. Apoptotic bodies, derived from dying cells, serve as initial substrates by exposing phosphatidylserine on their surfaces, which binds calcium and promotes the formation of calcium phosphate complexes. Matrix vesicles, extracellular organelles secreted by cells undergoing osteogenic differentiation, act as primary nucleation sites by concentrating calcium and phosphate ions within their lipid bilayers, initiating hydroxyapatite crystallization. Osteoblast-like cells, often arising from epithelial-mesenchymal transition in pathological contexts, further drive this by expressing osteogenic factors such as RUNX2 and bone morphogenetic protein 2 (BMP2), actively secreting mineralizing vesicles and upregulating alkaline phosphatase to hydrolyze phosphate precursors.^[25]^[26]^[21]^[10] The timeline of microcalcification formation spans from initial crystal deposition to maturation, typically unfolding over weeks to months in vivo, as modeled by in vitro studies of breast cancer cells. Early stages involve rapid nucleation within days, with amorphous calcium phosphate precursors forming around apoptotic bodies or matrix vesicles, followed by transformation into crystalline hydroxyapatite over 1-2 weeks. Maturation, including crystal growth and stabilization through carbonate substitution, extends to several weeks or months, influenced by local pH, ion availability, and cellular activity, resulting in detectable deposits on imaging.^[27]^[5]

Associated Risk Factors

Breast microcalcifications are more prevalent in postmenopausal women over the age of 50, with a marked predominance in females due to the higher incidence of breast tissue changes and hormonal influences post-menopause.^[5] This demographic pattern is particularly evident in mammographic detections, where age-related glandular involution contributes to calcium deposition in breast tissue.^[28] Medical conditions disrupting calcium-phosphate homeostasis significantly predispose individuals to microcalcification formation through metastatic mechanisms. Primary hyperparathyroidism elevates parathyroid hormone levels, leading to hypercalcemia and subsequent soft tissue calcium deposits.^[29] Chronic renal failure, often associated with secondary hyperparathyroidism, results in phosphate retention and elevated calcium-phosphate product, promoting ectopic calcification in vessels and organs.^[30] Excess vitamin D intake can induce hypercalcemia by enhancing intestinal calcium absorption, further increasing the risk of metastatic microcalcifications in normal tissues.^[31] Lifestyle factors influence microcalcification risk by altering metabolic and inflammatory pathways. Smoking accelerates vascular calcification through oxidative stress and endothelial damage, elevating the likelihood of coronary microcalcifications.^[32] Obesity, particularly abdominal adiposity, contributes via insulin resistance and chronic inflammation, fostering an environment conducive to calcium deposition in arteries.^[33] Dietary calcium imbalances, such as excessive supplementation without balanced intake, may raise serum calcium levels and promote soft tissue calcification, though evidence is stronger for cardiovascular than breast contexts.^[34]

Detection and Imaging Techniques

Mammography and Breast Imaging

Mammography serves as the primary modality for detecting breast microcalcifications during routine screening, leveraging the high attenuation of calcium deposits to produce bright white specks on images against the background of breast tissue. Standard screening protocols involve acquiring two orthogonal views of each breast: the craniocaudal (CC) view, which compresses the breast from top to bottom to capture the medial and lateral aspects including the inframammary fold, and the mediolateral oblique (MLO) view, angled at 40-60 degrees to include the axillary tail and pectoralis muscle. These views minimize superimposition of tissues, enhancing the visibility and localization of microcalcification clusters by allowing assessment from perpendicular angles, which is crucial for distinguishing true lesions from overlapping structures.^[35] Digital mammography has largely supplanted film-screen systems due to its superior performance in detecting microcalcifications, particularly in women with dense breasts where glandular tissue can obscure findings. In the Digital Mammographic Imaging Screening Trial (DMIST), digital mammography demonstrated higher accuracy than film-screen mammography for women under 50 years, those with heterogeneously or extremely dense breasts, and pre- or perimenopausal women, with area under the curve differences of 0.11 to 0.15 favoring digital systems. A multicenter study further showed that digital mammography increased cancer detection rates by approximately 14% overall compared to film-screen, with substantial improvements in identifying ductal carcinoma in situ (DCIS) and invasive carcinomas presenting as microcalcifications. This advantage stems from digital's higher spatial resolution and post-acquisition contrast adjustments, enabling better delineation of fine calcifications without the need for retakes.^[36]^[37] Digital breast tomosynthesis (DBT), often used in combination with synthetic mammography, provides multi-slice imaging to reduce tissue superposition, improving the characterization of microcalcification clusters. While detection sensitivity for individual microcalcifications may be slightly lower than full-field digital mammography (75–84%), DBT enhances specificity by better distinguishing benign from suspicious distributions, aiding BI-RADS assessment. As of 2025, DBT is standard in many screening protocols, particularly for dense breasts.^[38]^[39] For characterization of detected microcalcifications, additional diagnostic views such as magnification and spot compression are employed to refine morphology and distribution, aiding in BI-RADS classification. Magnification views, typically at 1.5-2x enlargement, position the breast closer to the x-ray source using a dedicated platform, improving resolution to evaluate the number, shape, and borders of individual calcifications, which helps differentiate benign from suspicious patterns. Spot compression applies targeted pressure to a specific area, reducing tissue thickness and motion artifact while displacing overlapping structures, thereby clarifying whether calcifications are real or summation artifacts. These techniques are essential in diagnostic workups following screening recalls.^[40]^[41] The sensitivity of mammography for detecting suspicious microcalcification clusters, a key indicator of DCIS, ranges from 85% to 98%, even in dense breasts where overall cancer detection may be challenged by parenchymal overlap, though calcifications' high contrast maintains reliable visualization. This performance underscores mammography's role as the cornerstone for early identification, prompting biopsy for clusters deemed suspicious on imaging.^[42]

Other Modalities

Computed tomography (CT) serves as a primary modality for detecting and quantifying coronary artery calcifications (CAC), which may include larger deposits but has limited resolution for true microcalcifications (<100 μm). Noncontrast, ECG-gated multislice detector CT is commonly used to identify granular calcium deposits as surrogates for atherosclerosis.^[43] The Agatston scoring method quantifies these calcifications by measuring the area of each lesion in square millimeters and multiplying by a density factor based on Hounsfield units (130-199 HU: factor 1; 200-299 HU: factor 2; 300-399 HU: factor 3; ≥400 HU: factor 4), with the total score derived from summing scores across 2.5-3 mm slices limited to the cardiac region.^[43] This approach assesses cardiovascular risk, where a score of zero predicts low event rates, and scores above 100 guide interventions like statin therapy, though it does not evaluate plaque vulnerability or stenosis degree directly.^[43] Ultrasound exhibits limitations in detecting microcalcifications due to its inability to penetrate dense calcium deposits and subjective quantification, rendering it ineffective for small lesions.^[44] However, it proves useful for vascular applications in superficial arteries like carotid or femoral, where it evaluates wall thickness, lumen size, and calcified plaques without radiation exposure, predicting cardiovascular events in chronic kidney disease patients with a prevalence of 71% in end-stage renal disease versus 21% in controls.^[45] Magnetic resonance imaging (MRI) with contrast enhances soft tissue differentiation in microcalcification assessment, particularly for vascular malformations and synovial sarcomas, by revealing hypointense calcifications on T1- and T2-weighted images alongside hyperintense fluid components.^[46] Post-contrast T1-weighted sequences demonstrate marked heterogeneous enhancement in lesions like synovial sarcoma, indicating associated vascularity through uptake in solid elements and necrotic areas, while venous malformations show diffuse delayed enhancement of slow-flow channels.^[46] Emerging dual-energy CT techniques enable material-specific imaging of calcium by decomposing tissues at two energy levels (e.g., 80/135 kV), improving detection of low-density microcalcifications in coronary arteries and reducing false negatives from 83.95% to 7.41% in low-density phantoms compared to standard Agatston scoring.^[47] These methods minimize beam-hardening artifacts, enhance plaque characterization over single-energy CT, and hold promise with photon-counting detectors for lower radiation doses and precise quantification of unstable microcalcifications as small as 5-65 μm.^[47]^[48]

Clinical Significance

In Breast Tissue

Microcalcifications in breast tissue represent a key radiological finding in breast pathology, often serving as an early indicator of underlying disease processes. They are primarily detected via mammography, where they appear as small calcium deposits less than 0.5 mm in diameter. Historically, their association with malignancy was first recognized in the 1930s through pioneering mammography studies, such as those by Stafford Warren, who demonstrated their potential in preoperative breast imaging and linked certain patterns to cancerous changes.^[49] A significant clinical role of breast microcalcifications lies in their strong association with ductal carcinoma in situ (DCIS), a non-invasive form of breast cancer. Approximately 70-90% of DCIS cases are identified through the presence of microcalcifications on mammograms, making them the most common imaging feature for this condition. These calcifications often arise from necrotic debris within ductal structures affected by DCIS, highlighting their utility in early cancer detection.^[50] While microcalcifications can signal malignancy, many are benign, stemming from non-cancerous conditions such as fibrocystic changes and sclerosing adenosis. Fibrocystic changes, prevalent in up to 50% of women over age 30, may produce clustered or punctate calcifications due to cyst formation and epithelial proliferation. Sclerosing adenosis, a proliferative lesion involving distorted lobules, commonly yields fine, granular microcalcifications that mimic malignant patterns on imaging.^[51]^[52] From a prognostic standpoint, the morphology and distribution of microcalcifications guide risk assessment and management decisions. Suspicious patterns, such as linear branching or fine pleomorphic forms classified under BI-RADS category 4, elevate concern for malignancy and prompt biopsy recommendations, with associated cancer detection rates ranging from 20-30% in certain descriptors. This variability underscores the need for careful radiologic-pathologic correlation to distinguish benign from malignant etiologies and inform biopsy rates.^[10]

In Cardiovascular System

Microcalcifications, often appearing as spotty or punctate deposits less than 3 mm in diameter, are commonly found within coronary atherosclerotic plaques and serve as key markers of instability. These small calcium fragments, typically ranging from 0.5 to 15 μm in size, develop during the early phases of intimal thickening and fibroatheroma formation, where they exert mechanical stress at the interface between calcified and soft plaque tissue, thereby promoting fibrous cap rupture and thrombus formation.^[53] Unlike extensive sheet-like macrocalcifications, which characterize stable, advanced lesions, microcalcifications indicate rupture-prone vulnerable plaques that heighten the risk of acute coronary events.^[54] The prognostic significance of coronary microcalcifications is substantial, with their presence linked to a more than 2-fold increased risk of plaque rupture and subsequent myocardial infarction. Specifically, spotty microcalcifications detected on computed tomography angiography have been associated with a hazard ratio of 2.25 (95% CI: 1.26–4.04) for plaque rupture events leading to acute coronary syndrome, underscoring their role in predicting adverse cardiovascular outcomes.^[55] This elevated risk persists independently of overall plaque burden, emphasizing microcalcifications as a distinct feature of high-risk atherosclerosis. Detection of microcalcifications in vulnerable coronary plaques relies on advanced intravascular imaging modalities. Intravascular ultrasound (IVUS) visualizes them as hyperechoic foci with acoustic shadowing, enabling assessment of their extent within the vessel wall, while optical coherence tomography (OCT) offers superior resolution to depict superficial microcalcifications as signal-poor regions with well-defined borders, facilitating identification in thin-cap fibroatheromas.^[53] These techniques are particularly valuable in guiding interventions for patients with acute coronary syndromes, where microcalcifications are more prevalent in culprit lesions. Microcalcifications in coronary plaques can progress over several years to larger macrocalcifications through coalescence and remodeling, a transition that generally correlates with improved plaque stability and reduced vulnerability to rupture. This evolution is influenced by factors such as inflammation resolution, often accelerated by statin therapy, which promotes the formation of denser, stabilizing calcium sheets while lowering event rates.^[53]

In Other Organs

Microcalcifications in the brain are most frequently observed in the pineal gland, where they manifest as benign, age-related deposits composed primarily of calcium and phosphorus. These calcifications are physiologic and increase in prevalence with advancing age, affecting approximately 58.8% of adults, with no significant correlation between age and the extent of calcification once present.^[56] In the lungs, microcalcifications often appear in the context of interstitial lung diseases, such as sarcoidosis, where they form part of a calcified micronodular pattern that simulates conditions like pulmonary alveolar microlithiasis.^[57] Similarly, in asbestosis, microcalcifications serve as markers of prior asbestos exposure, typically presenting as calcified pleural plaques or parenchymal nodules amid fibrotic changes.^[58] Renal microcalcifications are a hallmark of nephrocalcinosis, particularly in primary hyperoxaluria, a genetic disorder characterized by excessive hepatic production of oxalate leading to supersaturation and deposition of calcium oxalate crystals in the renal parenchyma. This process, observed in about 34% of patients with type 1 primary hyperoxaluria, directly contributes to tubular damage, interstitial fibrosis, and progressive renal dysfunction, elevating the risk of end-stage kidney disease.^[59] Microcalcifications in rarer sites include the thyroid gland, where they can develop post-radiation exposure, such as from therapeutic radioactive iodine or prior external beam radiation, often signaling underlying radiation-induced changes or increased malignancy risk in surveillance imaging.^[60] In the skin, dystrophic microcalcifications arise in areas of chronic tissue damage, such as burn scars or traumatic wounds, due to local deposition of calcium salts in necrotic or inflamed dermis without systemic metabolic derangements.^[61]

Diagnosis and Management

Diagnostic Approaches

Diagnostic approaches for microcalcifications, particularly in breast tissue, begin with targeted biopsy techniques once suspicious lesions are identified through imaging modalities like mammography. Stereotactic core biopsy is the preferred method for sampling non-palpable breast lesions associated with microcalcifications, guiding the needle using mammographic coordinates to precisely target the calcified area. Vacuum-assisted techniques enhance this procedure by enabling multiple contiguous samples from a single insertion, improving tissue yield and reducing the need for repeat biopsies. Vacuum-assisted stereotactic breast biopsy achieves high sampling accuracy, with calcification retrieval rates exceeding 95% in clinical studies, making it a reliable alternative to surgical excision for initial diagnosis.^[62] This method demonstrates diagnostic accuracy of approximately 97-98% for malignancy assessment in microcalcification cases, minimizing underestimation of atypical ductal hyperplasia or ductal carcinoma in situ.^[63] Post-biopsy, specimens undergo pathological examination to evaluate the underlying etiology. Pathological analysis routinely employs hematoxylin and eosin (H&E) staining to visualize calcium deposits, which appear as basophilic crystalline structures, and to identify associated epithelial changes such as atypia.^[64] This staining facilitates assessment of cellular morphology, distinguishing benign calcifications (e.g., in fibrocystic changes) from those linked to atypical hyperplasia or malignancy, where nuclear pleomorphism and architectural distortion are key indicators.^[65] Differential diagnosis involves ruling out imaging artifacts that can simulate true microcalcifications, such as those caused by skin powder, deodorant, or gridline errors in mammography; confirmation requires multi-view imaging and correlation with clinical history to ensure only genuine lesions proceed to biopsy.^[66] For microcalcifications deemed probably benign under BI-RADS category 3 (malignancy risk <2%), short-interval follow-up protocols recommend imaging at 6, 12, and 24 months to verify stability and avoid unnecessary interventions.^[67]

Treatment Strategies

Treatment strategies for microcalcifications vary depending on their etiology, location, and associated risks, with approaches tailored to address underlying conditions rather than the calcifications themselves in most cases. In breast tissue, management distinguishes between benign and malignant associations, prioritizing intervention for those linked to ductal carcinoma in situ (DCIS). For high-risk clusters suggestive of DCIS, surgical excision via lumpectomy or mastectomy is the primary treatment, often followed by radiation therapy and hormone therapy if estrogen receptor-positive. Emerging approaches, such as active surveillance in low-risk DCIS, are under investigation in clinical trials, with preliminary data indicating similar overall survival to surgical intervention as of 2024.^[68]^[69] In contrast, benign microcalcifications, which constitute the majority of findings, typically require only active surveillance through periodic mammography, as they pose no oncogenic risk and typically remain stable without progression.^[70]^[71] In the cardiovascular system, where microcalcifications signal unstable atherosclerotic plaques, direct removal is not feasible due to their integration into vascular walls; instead, therapies focus on plaque stabilization and risk factor modification. Statin therapy is the cornerstone, promoting regression of lipid-rich plaques while paradoxically increasing calcification density, which correlates with reduced plaque vulnerability and lower rates of acute coronary events.^[72] High-intensity statins, such as atorvastatin or rosuvastatin, are recommended for patients with coronary artery disease, achieving up to 30% relative risk reduction in major cardiovascular events over five years.^[73] For systemic causes driven by metabolic disorders like hypercalcemia or hyperparathyroidism, treatment targets the underlying hypermineralization to halt further deposition. Bisphosphonates, such as pamidronate or zoledronic acid, are administered intravenously to inhibit osteoclast activity and rapidly lower serum calcium levels, effectively managing hypercalcemia in conditions like primary hyperparathyroidism, which can help prevent further metastatic calcifications including in vascular tissues.^[74]^[24] In cases of parathyroid overactivity, parathyroidectomy offers definitive resolution by removing hyperfunctioning glands, preventing recurrent calcification and associated complications in over 90% of patients.^[75] Overall outcomes are favorable for benign microcalcifications, which typically remain stable under routine monitoring without intervention, avoiding unnecessary procedures. For malignant associations, such as DCIS, treatment aligns with oncology guidelines, yielding five-year survival rates near 98% post-surgery.^[71]^[68]

References

[1]
Microcalcifications - Pathology Outlines
Jul 29, 2024 · Breast microcalcifications are small deposits of calcium that measure < 0.5 mm in breast tissue and are visible on mammographic imagin.
[2]
Breast calcifications - Mayo Clinic
Breast calcifications are a buildup of calcium salts within breast tissue. They are common on mammograms. They appear as white spots or flecks on a mammogram.
[3]
Breast Calcification: Types, Causes, Tests & Treatment
not always — a sign of cancer in your breasts. But usually, calcifications are a sign of a benign condition. The good news ...
[4]
Understanding Breast Calcifications - Breast Cancer.org
Jan 30, 2024 · Calcifications are small deposits of calcium that show up on mammograms as bright white specks or dots on the soft tissue background of the breasts.Features Of Calcifications... · Appearance: Standard Sizes... · Assessment And Follow-Up...<|control11|><|separator|>
[5]
Mammographic microcalcifications and breast cancer tumorigenesis
Apr 22, 2015 · Microcalcifications (MCs) are tiny deposits of calcium in breast soft tissue. Approximately 30% of early invasive breast cancers have fine, ...<|control11|><|separator|>
[6]
Mammographic microcalcifications and risk of breast cancer - Nature
Jun 14, 2021 · Breast microcalcifications are deposits of calcium in the breast tissue and appear as small bright spots on mammograms [1]. Microcalcifications ...Materials And Methods · Measurement Of Mammographic... · Discussion
[7]
Breast Microcalcifications: Biological and Diagnostic Perspectives
Calcium deposits in breast tissues, called microcalcifications, may represent the very early and only sign of breast cancer lesions.
[8]
Differential of Breast Calcifications - The Radiology Assistant
Amorphous or indistinct calcifications are defined as 'without a clearly defined shape or form'. These calcifications are usually so small or hazy in appearance ...
[9]
Microcalcifications in breast cancer: an active phenomenon ...
Apr 23, 2014 · Type I calcifications are composed of calcium oxalate (CO), and ... Type II calcifications are composed of calcium phosphate, mainly ...
[10]
Microcalcifications in breast cancer: physiological mineralization
Two types of mammary microcalcifications have been identified and characterized on a molecular level; type I composed of calcium oxalate and type II composed of ...
[11]
Microcalcifications in Breast Cancer - News-Medical.net
Microcalcifications are a reliable early sign of breast cancer and can be detected with the help of mammography.
[12]
Mammogram - calcifications: MedlinePlus Medical Encyclopedia
Jan 15, 2025 · They are most likely not related to cancer. You will rarely need more testing. Microcalcifications are tiny calcium specks seen on a mammogram.
[13]
Breast microcalcifications: Past, present and future (Review) - PMC
Feb 10, 2022 · Mammary microcalcifications (MCs) are calcium deposits that are considered as robust markers of breast cancer when identified on mammography.Missing: threshold | Show results with:threshold
[14]
Breast calcifications | Radiology Reference Article - Radiopaedia.org
Jun 16, 2025 · Breast calcifications are deposits of calcium salts in the breast, which are radiopaque on mammography. The majority are benign, but they can be associated ...Missing: diameter | Show results with:diameter
[15]
Characterization of Breast Microcalcifications Using Dual-Energy ...
Calcium hydroxyapatite (Ca10(PO4)6(OH)2), or HAp, belongs to type II microcalcifications. It has a molecular weight of 1004.6 g/mol and a density of 3.18 g/cm3.2. Materials And Methods · 3. Results · 3.1. Mammography Planar...<|control11|><|separator|>
[16]
Breast Calcifications: The Focal Group | AJR
Most breast calcifications are deposits of calcium phosphate, usually in the form of hydroxyapatite. These stain dark blue to purple on routine H and E ...
[17]
Shape-dependent toxicity and mineralization of hydroxyapatite ... - NIH
Dec 12, 2019 · In this study, we compared the differences in toxicity of four various morphological nano-HAP crystals, namely, H-Rod, H-Needle, H-Sphere, and H-Plate, in rat ...
[18]
Characterization of Calcium Phosphate Spherical Particles in the ...
Micrometer-sized spherules formed of hydroxyapatite or whitlockite were identified within extracellular deposits that accumulate in the space between the ...
[19]
Elemental vs. phase composition of breast calcifications - PMC
Mar 9, 2017 · “Type 2” calcifications are composed of calcium phosphate with an apatite structure; these are much more common, and are sometimes, but not ...Missing: threshold | Show results with:threshold
[20]
Computer aided detection of microcalcifications in digital ...
The calcifications vary in size from smaller than 0.1 mm to 5 mm in diameter, and a radiologist must carefully examine the mammogram with a magnifier to locate ...
[21]
(PDF) Threshold pixel size for shape determination of ...
Aug 6, 2025 · For CR images, half the shapes were not properly identified. Hence, although 20-100 microm was sufficient for microcalcification shape ...
[22]
[PDF] Computer-aided detection and classification of microcalcifications in ...
The sizes of micro- calcifications are in the range of 0.1–1:0 mm, and the average is about 0.3 mm. Some isolated ones smaller than 0.1 mm cannot be ...
[23]
Polyhedral microcalcifications on mammograms
Microcalcifications ranged from 200 to 700 tm. B, Histologic specimen under polarized light. Calcium oxalate rnicrocalcifications. (arrows) are located in cysts ...
[24]
Molecular Aspects and Prognostic Significance of Microcalcifications ...
Dec 24, 2020 · This narrative review highlights the most recent histopathological and molecular data concerning the formation of calcifications in breast, thyroid, lung, and ...
[25]
Radiological identification and analysis of soft tissue ...
Jun 7, 2018 · Dystrophic calcifications occur in necrotic or damaged tissue with normal serum levels of calcium and may progress to ossification. They ...<|control11|><|separator|>
[26]
Fatal Generalized Metastatic Calcifications - PMC - NIH
Metastatic calcifications, first described by Virchow in 1855, are abnormal depositions of calcium salts in healthy tissues due to hypercalcemia and ...Missing: mechanism | Show results with:mechanism
[27]
Hypercalcemia and metastatic calcification - Oxford Academic
Linear calcification of medium and large arteries develops gradually during renal failure, causes narrowing of the lumen and ends in amputation for a ...Missing: mechanism microcalcification
[28]
Apoptosis regulates human vascular calcification in vitro - PubMed
These observations provide evidence that apoptosis precedes VSMC calcification and that apoptotic bodies derived from VSMCs may act as nucleating structures for ...Missing: microcalcification | Show results with:microcalcification
[29]
Matrix Vesicles as a Therapeutic Target for Vascular Calcification
Jan 20, 2022 · This article aims to review the detailed role of MVs in the progression of VC and compare the difference with other major drivers of calcification.
[30]
A time-course Raman spectroscopic analysis of spontaneous in vitro ...
Jun 11, 2021 · The timeline and stages of mineralization in breast microcalcifications ... formation of microcalcifications within breast tissues. A further ...
[31]
Predictors of mammographic microcalcifications - PMC - NIH
Among lifestyle risk factors, women with a body mass index ≥30 kg/m2 had the lowest risk of microcalcification clusters OR = 0.79 (95% CI = 0.73‐0.85) and the ...Missing: demographic | Show results with:demographic
[32]
Soft tissue calcifications: a pictorial essay - PMC - NIH
Other causes of metastatic calcifications with disorders of calcium and phosphate metabolism include primary hyperparathyroidism, milk-alkali syndrome, and ...
[33]
Metastatic Calcification - an overview | ScienceDirect Topics
Metastatic calcification of the soft tissues in the oral region is caused by conditions involving elevated serum calcium and phosphate levels, such as ...
[34]
Metastatic calcification – Knowledge and References
Common causes of hypercalcaemia include overproduction of parathyroid hormone (for example by a parathyroid adenoma), vitamin D intoxication and excessive ...
[35]
Association between Metabolic Syndrome, Smoking Status and ...
MS is correlated with an increased risk of CAC, and a combination of MS and smoking is associated with even greater risk.
[36]
Lifestyle Factors and Coronary Artery Calcification - Karger Publishers
Mar 12, 2015 · Excess adiposity is mainly due to unhealthy diets and sedentary lifestyles. Particularly, abdominal obesity is a significant risk factor for ...Missing: microcalcification | Show results with:microcalcification
[37]
Calcium Intake From Diet and Supplements and the Risk of ...
Oct 11, 2016 · Recent randomized data suggest that calcium supplements may be associated with increased risk of cardiovascular disease (CVD) events.Missing: microcalcification | Show results with:microcalcification
[38]
Association of common variants in the calcium-sensing receptor ...
May 14, 2015 · Loss-of-function mutations of the CASR gene on chromosome 3q are associated with familial hypocalciuric hypercalcemia and hyperparathyroidism.
[39]
Diseases associated with calcium-sensing receptor
Jan 25, 2017 · The genetic diseases consist of hyper- or hypocalcemia disorders. Hypercalcaemia disorders are related to inactivating mutations of the CASR ...
[40]
Mammography - StatPearls - NCBI Bookshelf - NIH
There are two standard views in screening mammography, named for the direction of the x-ray beam from the source to detector: craniocaudal (CC) and mediolateral ...
[41]
Diagnostic Performance of Digital versus Film Mammography for ...
Oct 27, 2005 · Digital mammography is more accurate in women under the age of 50 years, women with radiographically dense breasts, and premenopausal or perimenopausal women.
[42]
Comparison of Digital Screening Mammography and Screen-Film ...
Dec 1, 2012 · The performance of digital mammography in the detection of DCIS and invasive carcinoma was substantially better than that of screen-film mammography.
[43]
Magnification view (mammography) | Radiology Reference Article
Dec 29, 2011 · A magnification view in mammography is performed to evaluate and count microcalcifications and its extension (as well the assessment of the borders and the ...
[44]
Microcalcification on mammography: approaches to interpretation ...
Magnification views can be used to enhance the morphology of calcifications. ... mammography are recalled for assessment, including further views ...
[45]
Mammographic Vascular Microcalcifications as a Surrogate ... - NIH
Dec 13, 2024 · An proportion of 0–40% of breast cancers exhibit microcalcifications [10]. Microcalcifications (MC) are responsible for detecting 85–95% of ...
[46]
Coronary Artery Calcification - StatPearls - NCBI Bookshelf
Nov 8, 2024 · The Agatston score is the most validated method of CAC quantification. The total CAC is calculated by summing individual calcification speck ...
[47]
Coronary Artery Microcalcification: Imaging and Clinical Implications
Since IVUS cannot penetrate calcium, its assessment is limited to arc and length. Another limitation is the inability to assess the composition and inflammation ...
[48]
Role of different imaging modalities of vascular calcification in ... - PMC
Ultrasonography is suitable for calcification in superficial arteries. Analyses of wall thickness and lumen size are also possible. Computed tomography (CT) ...Missing: microcalcifications | Show results with:microcalcifications
[49]
Imaging Features of Soft-Tissue Calcifications and Related Diseases
Soft-tissue calcification refers to a broad category of lesions. Calcifications are frequently identified by radiologists in daily practice.
[50]
Coronary artery calcium quantification technique using dual energy ...
Jun 21, 2024 · Dual-energy CT has the potential to minimize the impact of these artifacts on CAC quantification. The material decomposition capabilities of ...
[51]
Advances in CT Techniques in Vascular Calcification - PMC - NIH
A microcalcification size of only between 5 and 65 μm is sufficient to make the plaque unstable (86). However, ordinary CT cannot effectively detect ...
[52]
History of Mammography: Analysis of Breast Imaging Diagnostic ...
May 30, 2023 · Shortly after, in 1930, Stafford Warren (1896–1981) performed the first mammogram in the United States. The radiologist analysed the potential ...
[53]
Ductal Carcinoma In Situ of the Breast: An Update with Emphasis on ...
Mar 6, 2020 · Several studies show that the diagnosis of DCIS mainly depends on the detection of microcalcifications on mammographic screening (70–90% of ...<|control11|><|separator|>
[54]
Calcification in breast lesions: pathologists' perspective - PubMed
Fibroadenoma may be associated with large popcorn like calcifications, and sclerosing adenosis may have fine, punctate or granular calcifications.
[55]
Fibrocystic Breast Disease - StatPearls - NCBI Bookshelf - NIH
Proliferative changes include factors such as Intraductal hyperplasia, sclerosing adenosis, radial scars, and papillomas.
[56]
Coronary Artery Microcalcification: Imaging and Clinical Implications
Sep 23, 2019 · Microcalcifications develop in the earliest stages of coronary intimal calcification and directly contribute to plaque rupture producing local ...Missing: unstable | Show results with:unstable
[57]
Coronary Artery Calcification: Current Concepts and Clinical ...
Jan 16, 2024 · Some patterns of calcification such as microcalcification portend increased risk of rupture and cardiovascular events and may improve prognosis ...
[58]
Coronary artery calcification: More than meets the eye - PMC - NIH
Mar 13, 2020 · Conversely, spotty calcification on CT is associated with > 2-fold ... Identifying active vascular microcalcification by (18)F-sodium fluoride ...
[59]
Prevalence of pineal gland calcification as an incidental finding in ...
Sep 21, 2017 · The prevalence of pineal gland calcification was 58.8%. There was no statistically significant correlation between age and the extent of the ...
[60]
The calcified lung nodule: What does it mean? - PubMed Central - NIH
Peripheral bronchogenic tumors complicating asbestos lung ... Pulmonary sarcoidosis: Calcified micronodular pattern simulating pulmonary alveolar microlithiasis.
[61]
Imaging of asbestos-related lung and pleural diseases as an ...
Mar 31, 2020 · The aim of our study is to detect and evaluate the different radiological patterns of asbestos-related lung and pleural disease and its complications
[62]
Nephrocalcinosis is a risk factor for kidney failure in primary ... - NIH
Sep 17, 2014 · Nephrocalcinosis was found in 34% of patients, including 41% with type 1 primary hyperoxaluria. High urine oxalate was associated with increased ...Missing: microcalcifications | Show results with:microcalcifications
[63]
Symptomatic calcification of a thyroid lobe and surrounding tissue ...
Conclusion: We report an unusual replacement of the thyroid remnant with calcification that developed over a period of 16 years following radioactive iodine ...Missing: microcalcifications post-<|separator|>
[64]
Late‐onset calcinosis in burn scars: A review of the literature ... - PMC
It may be classified as dystrophic calcification in the absence of alterations in serum calcium and phosphate levels.
[65]
Calcification retrieval at stereotactic, 11-gauge, directional, vacuum ...
CONCLUSION: Stereotactic, 11-gauge, directional, vacuum-assisted biopsy resulted in successful calcification retrieval in 106 (95%) of 112 cases. Histologic ...Missing: percentage | Show results with:percentage
[66]
Value of stereotactic 11-gauge vacuum-assisted breast biopsy in ...
Stereotactic 11G-VABB might be preferred for the investigation of non-palpable mammographically-detected calcifications in terms of accuracy and safety profile.<|control11|><|separator|>
[67]
microcalcifications, more columnar cell lesions without atypia - Nature
May 13, 2011 · Pathology. The original hematoxylin-and-eosin-stained slides from all 3437 female breast core needle biopsies were reviewed by two ...
[68]
Epithelial atypia in biopsies performed for microcalcifications ... - PMC
For each SB and each lesion, we prospectively entered in our pathologic database morphological descriptive criteria by using 65 pathological items for ...
[69]
Artifacts and Pitfalls in Breast Imaging | Radiology Key
Apr 7, 2016 · These artifacts may be due to incorrect collimation, incomplete grid motion, Bucky failure, and compression system failure.Missing: differential | Show results with:differential
[70]
BI-RADS 3: Current and Future Use of Probably Benign - PMC - NIH
Jan 27, 2018 · ... calcification morphology causing them to appear more suspicious should prompt a biopsy recommendation [16]. For BI-RADS 3 to be properly ...
[71]
Treatment of Ductal Carcinoma in Situ (DCIS)
Most women with DCIS can be cured with surgery, sometimes followed by radiation therapy and/or hormone therapy.
[72]
Benign Breast Calcifications - StatPearls - NCBI Bookshelf - NIH
Aug 7, 2023 · Breast calcifications are extremely common. It is important to be able to differentiate between benign and malignant calcifications because ...Missing: timeline | Show results with:timeline
[73]
Effects of Statins on Coronary Atherosclerotic Plaques - PubMed - NIH
Statins were associated with slower progression of overall coronary atherosclerosis volume, with increased plaque calcification and reduction of high-risk ...Missing: microcalcification | Show results with:microcalcification
[74]
Association of Statin Treatment With Progression of Coronary ... - NIH
Aug 18, 2021 · The results suggest an association of statin use with greater rates of transformation of coronary atherosclerosis toward high-density calcium. A ...
[75]
Medical management of hypercalcaemia - PMC - NIH
Intravenous bisphosphonates are the treatment of first choice for the initial management of hypercalcaemia, followed by continued oral, or repeated intravenous ...Missing: vascular | Show results with:vascular
[76]
The role of parathyroidectomy in treating hypertension and other ...
The only definitive treatment for PHPT is surgery. Medications such as calcimimetics and bisphosphonates can be used to treat hypercalcemia and osteoporosis ...
[77]
4 questions about breast calcifications, answered | MD Anderson ...
Nov 18, 2021 · “There aren't risk factors or lifestyle factors that cause calcifications as far as we know,” Dryden says. The best way to be aware of them is ...